Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026)
Caribou Biosciences' (CRBU) quarterly Income from Continuing Operations came in at 28109000.0 in Q1 2026, up 34.68% year-on-year from 20871132.57 in Q1 2025, and up 2.77% on a QoQ basis from 28909000.0 in Q4 2025.
Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Income from Continuing Operations data on file, last reported at 28109000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 34.68% year-over-year to 28109000.0 in Q1 2026; TTM through Mar 2026 was 137157000.0, a 36.51% increase from a year earlier, with the FY2025 full-year figure at 148125000.0, up 0.66% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 28109000.0, up from 28909000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for CRBU reached as high as 22678000.0 in Q1 2022 and fell as low as 87360000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 46902117.65 across 5 years, with a median of 40307000.0 in 2024.
- Across the five-year window, Income from Continuing Operations sank 431.74% in 2022 and jumped 57.42% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 31075000.0 in 2022, then retreated by 20.89% to 37566000.0 in 2023, then decreased by 7.3% to 40307000.0 in 2024, then rose by 28.28% to 28909000.0 in 2025, then advanced by 2.77% to 28109000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 28109000.0 in Q1 2026, 28909000.0 in Q4 2025, and 32398000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Caribou Biosciences | 156.25 Mn | 38.63 Mn | - | -28.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.11 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -32.40 Mn |
| Jun 30, 2025 | -47.74 Mn |
| Mar 31, 2025 | -43.03 Mn |
| Dec 31, 2024 | -40.31 Mn |
| Sep 30, 2024 | -76.10 Mn |
| Jun 30, 2024 | -56.59 Mn |
| Mar 31, 2024 | -87.36 Mn |
| Dec 31, 2023 | -37.57 Mn |
| Sep 30, 2023 | -29.88 Mn |
| Jun 30, 2023 | -76.67 Mn |
| Mar 31, 2023 | -31.42 Mn |
| Dec 31, 2022 | -31.08 Mn |
| Sep 30, 2022 | -51.42 Mn |
| Jun 30, 2022 | -76.10 Mn |
| Mar 31, 2022 | -22.68 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |